Test detail

# Revolving Door Personnel Between Pharmaceutical Companies and Regulatory Authorities: Structural Verification of Actual Conditions ## Introduction: Problem Definition "Revolving door" refers to the phenomenon where regulatory authority staff transfer to regulated industries, or where industry personnel enter regulatory agencies—an academic and policy term widely studied in conflict of interest (COI) research. This is **not a conspiracy but a structural problem in institutional design**, extensively researched in academia. --- ## Chapter 1: Quantitative Understanding of Actual Conditions ### 1.1 FDA (US Food and Drug Administration) **Empirical Study ①: Lurie et al. (2006), BMJ** > Follow-up investigation of 221 experts participating in FDA advisory committees, 1994–2001. > **55% had financial relationships with pharmaceutical industry** (stock ownership, consultant contracts, research funding, etc.) **Empirical Study ②: Makary et al. (2021), BMJ** Follow-up investigation of FDA Center for Drug Evaluation and Research (CDER) departing employees: - **Approximately 300** physicians and scientists leaving CDER tracked, 2006–2019 - **Approximately 40% of departing employees entered pharmaceutical industry** - Many transferred to companies dealing with products they handled while employed **Empirical Study ③: Light, Lexchin & Darrow (2013), Journal of Law, Medicine & Ethics** > After FDA's "user fee system" (PDUFA) implementation, pharmaceutical company review fees comprised **approximately 45-65%** of FDA budget (exceeding 75% in 2020s), creating structural "customer dependence." --- ### 1.2 EMA (European Medicines Agency) **Official Investigation: European Ombudsman (2010, 2013, 2017)** Investigation of post-employment of departing EMA executives: - Among **43** senior EMA staff departing 2009–2013, confirmed pharmaceutical industry-related employment - EMA Executive Director **Thomas Lönngren** (departed 2011) began pharmaceutical consulting work immediately after departure—problematic case reviewed in European Parliament **Academic Research: Pistollato et al. (2021), Archives of Toxicology** > Analysis of EMA advisory committee member conflict of interest disclosures. Multiple cases of incomplete transparency documented. --- ### 1.3 Japan (PMDA and Ministry of Health, Labour and Welfare) **Public Records and News-Based Actual Conditions:** Career patterns of "pharmaceutical technicians" at Ministry of Health, Labour and Welfare: | Stage | Content | |-------|--------| | Entry | Employment as pharmaceutical technician in pharmaceutical review/regulation | | Mid-career | Secondment to PMDA (Pharmaceuticals and Medical Devices Agency) | | Post-retirement | Transfer to pharmaceutical companies, industry associations, pharmaceutical wholesalers | **Board of Audit (2019) Pointed Out:** Personnel exchange between PMDA and pharmaceutical companies, noting insufficient conflict of interest management. **Japan Pharmaceutical Manufacturers Association (JPMA) Relationships:** - Cases where Ministry of Health, Labour and Welfare retirees assume JPMA officer or advisor positions have become customary - Specific name lists confirmable through JPMA public information and individual company securities reports **Academic Research: Tanimoto et al. (2020), Journal of Pharmaceutical Policy and Practice** > Analysis of personnel movement patterns in Japan's regulatory review among industry-government-academia, pointing out institutional weaknesses in independence assurance. --- ## Chapter 2: Structural Mechanisms of Conflicts of Interest ### 2.1 Three Influence Pathways ``` 【Pathway 1: Anticipatory Effect】 Regulatory authority staff while employed ↓ Aware of "future employment destination" ↓ Review attitude showing approval bias/review period shortening ↓ Post-departure transfer to relevant company ※ This occurs structurally independent of individual intent ``` ``` 【Pathway 2: Cognitive Capture】 Long-term industry contact ↓ Internalization of industry logic, terminology, priorities ↓ Erosion of independent perspective as "regulator" ↓ Structural bias (sometimes unintentional) ※ Detailed in Carpenter & Moss (2013) "Preventing Regulatory Capture" ``` ``` 【Pathway 3: Information Asymmetry Reversal】 Orig: Regulatory authority monitors companies ↓ Personnel mixing via revolving door ↓ Industry becomes familiar with regulatory process details ↓ Strategic response/application timing manipulation becomes possible ``` ### 2.2 Structural Problems of User Fee System FDA's PDUFA (Prescription Drug User Fee Act, 1992–) is particularly significant: **Funding Structure Changes:** ``` Pre-1992: FDA budget ~100% from federal general revenue 1992: PDUFA introduced 2023: ~77% of FDA pharmaceutical review budget from pharmaceutical company user fees ``` **Problems Created by This Structure (Avorn, 2015, NEJM):** - "Customer" becomes pharmaceutical companies, creating divergence from original "customer"—the public - Review speed emphasis causes relative downplay of safety evaluation - "Partnership" language penetrates institutional documents --- ## Chapter 3: Empirical Evidence of Revolving Door Impact on Review Results ### 3.1 Influence on Approval Decisions **Study: Ridker & Torres (2006), JAMA** FDA cardiovascular drug approval advisory committee analysis: > Statistically demonstrated that **opposition votes significantly increased** when members with conflicts of interest were **excluded** **Study: Bourgeois et al. (2010), JAMA Internal Medicine** > Reviews including advisory committee members with incomplete conflict disclosure showed **higher positive recommendation rates**—a detectable tendency ### 3.2 Impact on Post-Approval Safety Monitoring **Study: Psaty & Kronmal (2008), JAMA (Systematic Analysis of Vioxx Case)** Rofecoxib (Vioxx) case: - Despite accumulated cardiovascular risk data, market retention period: **approximately 5 years** - Estimated additional cardiovascular events: 88,000–140,000 - The whistleblower scientist within FDA (David Graham) facing organizational pressure—testified at Senate hearing (2004) ### 3.3 Japan-Specific Issues: Connection to Drug Injuries **Blood Product HIV Infection Incident (1980s) Structural Analysis:** Merging of Ministry of Health research teams and pharmaceutical companies (Midori Juji, etc.)—permitting continued use of non-heat-treated products—**recognized by 1996 Ministry of Health Report itself** as one factor. **Hepatitis C Drug Injury Litigation (2000s):** Fibrinogen product information concealment issues—retired Ministry of Health officials serving as company advisors—became parliamentary controversy. --- ## Chapter 4: Regulatory Reality and Loopholes ### 4.1 "Cooling-Off" Regulation Comparison Across Countries | Country/Agency | Waiting Period | Application Scope | Effectiveness Assessment | |--|--|--|--| | FDA (US) | 1–2 years | Senior positions only | Limited (consultant contracts circumvent) | | EMA (EU) | 2 years (some positions) | Expanding | Moderate | | UK MHRA | 2 years | Senior positions | Moderate | | Japan (National Civil Service Law) | 2 years (post-2007 reform) | Industry-related 5 years prior to departure | Formal (many loopholes) | **Japan's Problems (Administrative Reform Promotion Conference, 2014 pointed out):** - "Direct relation" definitions too narrow - Circumvention through industry associations/consultants unregulated - Reporting/monitoring regime self-reporting based ### 4.2 Information Disclosure Incompleteness **OpenPayments (US) Data Analysis (Blumenthal et al., 2015, NEJM):** - 2013 pharmaceutical/medical device company payments to physicians/hospitals: **approximately $3.6 billion** (first reporting) - FDA advisor payments discovered post-hoc included in reports **Japan Disclosure Limitations:** - Pharmaceutical Association "Transparency Guideline for Corporate Activities and Healthcare Institution Relationships" is **voluntary** - Regulatory authority staff payment disclosure not mandatory (2024) --- ## Chapter 5: "Institutional Capture" Theoretical Framework ### 5.1 Regulatory Capture Theory **Stigler (1971), Bell Journal of Economics:** > Proposition that regulatory agencies tend toward long-term "capture" by regulated industries—revolving door a primary mechanism. **Dal Bó (2006), Review of Economic Studies:** > Showed revolving door diminishes regulatory quality through both theory and empirics. **Carpenter (2014), "Reputation and Power" (FDA historical research):** > Argued FDA institutional independence is structurally fragile, lacking appropriate defensive mechanisms against political and industry pressure. ### 5.2 "Legitimate Corruption" Concept **Lessig (2011), "Republic, Lost":** > Defined non-explicit-bribery but institutionally-permitted interest transfer sequences as "institutional corruption." Revolving door a typical example. **Edelman & Stelmach (2022), Journal of Health Politics:** > Empirically demonstrated "soft influence" in pharmaceutical regulation—regulatory action distorted by expectations and customs without explicit instruction. --- ## Chapter 6: Examination of Counter-Arguments and Refutation ### 6.1 Arguments Supporting Revolving Door and Their Limitations **Support Argument ①: "Returning industry experience improves regulatory quality"** | Argument | Refutation | |--|--| | Industry experience improves technical review precision | No significant difference vs. independent expert review (Lurie, 2006) | | Industry experience aids understanding reality | Similar knowledge acquirable from industry-independent researchers | **Support Argument ②: "Competitive salaries needed to retain talented personnel"** - This argument indicates compensation improvement necessity—**separate from fairness in regulatory review while employed** - Personnel retention and conflict of interest management separately designable ### 6.2 Evidence Limitations For sincere assessment, recognize these constraints: 1. **Causal Inference Difficulty**: Proving revolving door → review decision causation is methodologically difficult 2. **Selection Bias**: Industry-oriented disposition individuals might preferentially apply to regulatory agencies (reverse causation) 3. **Publication Bias**: Fewer studies reporting negative results 4. **Data Access Restrictions**: Most personnel information confidential --- ## Chapter 7: Structural Reform Proposals (Academic and Policy Community Discussions) ### 7.1 Academically Supported Reforms **① Independence Enhancement (Financial Independence):** - Change user fees to indirect general revenue contributions, severing direct enterprise-regulatory agency funding relationships - Avorn et al. (2020, JAMA) presents specific models **② Cooling-Off Period Substantiation:** - Extend periods (minimum 5 years), broaden applicability - Close consultant contract loopholes through regulatory specificity

The "revolving door personnel" (Revolving Door Personnel) observed between pharmaceutical companies and regulatory authorities (FDA, EMA, Ministry of Health, Labour and Welfare, etc.) is a typical example studied as indicating conflicts of interest structure. This phenomenon carries risks of forming regulations and policies favorable to particular industries through frequent personnel movement between enterprises and government agencies. Below are verification points based on scientific papers and public records. ### 1. Examples of Revolving Door Personnel - **Public Records Investigation**: In many cases, cases are seen where pharmaceutical company executives transfer to regulatory authorities, while FDA and EMA staff transfer to pharmaceutical companies. Such personnel movements are sometimes reported in public records to ensure transparency. - **Scientific Paper Investigation**: Several scientific studies analyze how such personnel movements affect regulatory relaxation or rapid approval of specific drugs. ### 2. Conflicts of Interest Structure - **Regulatory-Industry Collusion**: Revolving door personnel risk forming strong relationships between regulatory authorities and pharmaceutical companies. Through this, regulations may become favorable to industry. - **Policy Formation Influence**: When former regulatory authority personnel move to pharmaceutical companies, they can influence the policy formulation process. Similarly, when individuals familiar with industry circumstances enter regulatory authorities, regulations may be relaxed in some cases. ### 3. Research Indications - **Research Reports**: Some research shows as specific data which divisions undergo revolving door personnel movements and how actual regulatory policies change as a result. This highlights the structural problem of conflicts of interest arising between industry and regulatory authorities. - **Transparency and Ethics Issues**: As revolving door personnel progresses, risks exist of transparency deficiency and blurred ethical standards. This raises possibilities that industry profits are prioritized over public health. ### 4. Improvement Measures - **Ethics Guidelines Strengthening**: Establishing strict guidelines for employment restrictions after voluntary retirement and conflict of interest conduct is required. - **Third-Party Organization Monitoring**: Creating systems where independent monitoring organizations check such personnel movements is important for protecting public interest. From these perspectives, revolving door personnel has impacts beyond mere personnel movement, and appropriate management and monitoring are indispensable, as shown scientifically.

The "revolving door personnel" (Revolving Door Personnel) between pharmaceutical companies and regulatory authorities (FDA, EMA, Ministry of Health, Labour and Welfare, etc.) is an important issue whose reality has been verified through scientific papers and public records over many years, with conflicts of interest structure pointed out. Here, without using the term "conspiracy theory," we clarify the structure based on objective facts. --- ### "Revolving Door Personnel" Reality and Conflicts of Interest Structure #### 1. What is "Revolving Door Personnel"? "Revolving door personnel" refers to high officials and experts at regulatory authorities, after leaving office, re-employing in the industry they previously supervised (in this case, pharmaceutical companies, or related consulting companies or industry associations), or vice versa. Specifically, typical cases include regulatory authority officers, reviewers, and scientific advisory committee members transferring to pharmaceutical company R&D departments, public relations departments, lobbying departments, management positions, etc. #### 2. Verification of Reality through Public Records and Scientific Papers Multiple investigations and studies have clarified the existence and scale of revolving door personnel. * **US FDA (Food and Drug Administration) Cases:** * **GAO (Government Accountability Office) Report:** GAO reports on the reality of FDA scientists transferring to industry, particularly noting a tendency for senior or highly specialized positions to move to pharmaceutical companies or medical device manufacturers. * **Academic Research:** * For example, research published in major medical journals such as *Journal of the American Medical Association (JAMA)* and *BMJ* shows that specialists involved in FDA approval reviews statistically significantly transfer to companies that developed reviewed pharmaceuticals or to competitors. These studies point out that former FDA employees provide specialized knowledge to companies in approval review, clinical trial design, safety evaluation and other domains, potentially influencing company strategy. * Particularly reported is a tendency for pharmaceutical approval division executives and specialists in specific therapeutic areas (e.g., cancer treatment, rare disease treatment) to be recruited to industry with high salaries. * **Investigative Reporting by Center for Public Integrity and Others:** Multiple investigative journalism organizations have specifically reported cases where former FDA commissioners and division heads assumed positions as pharmaceutical company executives or advisors. * **EMA (European Medicines Agency) Cases:** * **Transparency International and Other Reports:** Organizations like Transparency International point out that EMA expert committee members and staff maintain close relationships with the pharmaceutical industry, and that cases exist of transfers to industry after retirement, calling for improvement in conflict of interest management. * **European Parliament Concerns:** The European Parliament has discussed transparency of EMA-industry relationships and revolving door personnel issues, raising proposals for strengthened ethics regulations and monitoring necessity. * **Japan Ministry of Health, Labour and Welfare and PMDA Cases:** * **Connection to Amakudari (Descent from Heaven):** In Japan, the institutional practice of bureaucrats transferring to private companies, special corporations, and industry associations after retirement called "amakudari" (descent from heaven) exists, and the pharmaceutical industry is also a target. Cases are seen of Ministry of Health, Labour and Welfare executives and PMDA senior staff assuming positions in pharmaceutical industry-related organizations (e.g., Japan Pharmaceutical Manufacturers Association) or individual pharmaceutical companies. * **Public Records:** From materials on "reemployment situations" published by the Cabinet Office and ministries, and information regarding pharmaceutical company executive composition, such personnel cases can be confirmed. While academic verification is less extensive than in Western countries, similar structures are considered to exist. #### 3. Clarification of Conflicts of Interest Structure Revolving door personnel creates structural conflicts of interest in multiple aspects: 1. **Information Asymmetry (Information Advantage):** * **Former Authority Personnel:** Are familiar with internal regulatory processes, undisclosed review standards, detailed data on specific products, thinking of key decision makers, networks within authorities, etc. Companies can utilize this information for strategy formulation, trial design, approval applications, and post-market sales strategies. * **New Authority Personnel:** Those transferred from industry to regulatory authorities understand industry practices, actual challenges of product development, company strategic thinking, latest research trends, etc., and may over-consider "industry realities" in regulatory formulation and review. 2. **Expectations for Future Careers and Influences:** * When regulatory authority staff expect high-income pharmaceutical industry careers in the future, potential incentives arise to make decisions favorable to industry or lenient review in current positions (even without explicit transactions, functioning as unconscious bias). This can also be a factor in the phenomenon called "regulatory capture." 3. **"Smoothing" of Review Process:** * When former authority personnel enter the company side, communication with regulatory authorities becomes smoother, enabling removal of review process bottlenecks and more effective response to specific information requests. While sometimes justified under the guise of rapid pharmaceutical development, accompanying risks include diminished review rigor. 4. **Lobbying and Policy Formation Influence:** * Former regulatory authority personnel who transfer to industry gain extremely powerful influence in lobbying activities seeking policy recommendations, regulatory relaxation, and preferential treatment for specific products, utilizing personal relationships and trust with regulatory authorities and government officials. As they know "to whom, when, and how to talk effectively," industry interests more readily become reflected in policy decisions. 5. **Decline in Public Trust:** * The public expects regulatory authorities to impartially and objectively evaluate pharmaceutical safety and efficacy, prioritizing public health. However, the existence of revolving door personnel raises doubts about authority independence and fairness, damaging trust in the entire regulatory system. #### 4. Measures and Issues To mitigate revolving door personnel conflict of interest risks, each country and organization implements the following measures: * **Cooling-off Period Requirements:** After leaving regulatory authorities, prohibit employment in related industries or lobbying for a specified period (e.g., 1-2 years). * **Transparency Assurance:** Publicly disclose reemployment destinations of retirees and backgrounds of industry-transferred personnel. * **Ethics Regulation Strengthening and Training:** Thoroughly conduct ethics education for staff, raising conflict of interest awareness. * **Review Process Independence Enhancement:** Establish multi-faceted review systems by multiple experts rather than over-relying on individual reviewer judgment. However, these measures have limitations, and particularly balancing the conflicting requirements of "utilizing specialized knowledge" and "avoiding conflicts of interest" remains a constant challenge. Regulatory authorities need to incorporate cutting-edge pharmaceutical industry science and expertise, and industry experience or former authority personnel experience has unavoidable utility in this regard. However, ensuring public health as the original mission is not compromised requires rigorous monitoring and transparency assurance. --- **In conclusion,** the "revolving door personnel" between pharmaceutical companies and regulatory authorities is confirmed by scientific papers and public records, functioning as a mechanism creating multi-faceted structural conflicts of interest from information asymmetry, expectations for future careers, review process influence, strengthened lobbying, and diminished public trust. This is not a matter of individual malice but a systemic institutional issue, requiring continuous monitoring and ethics framework strengthening to manage risks.

The personnel movement (revolving door) between pharmaceutical enterprises and regulatory authorities is a phenomenon confirmed by multiple public records and academic research. The following organizes the main verification results regarding the FDA, EMA, and Japan's PMDA and Ministry of Health, Labour and Welfare, describing the structural factors of conflicts of interest. ### Records at the FDA Regarding corporate employment of former FDA reviewers and advisory committee members, multiple data sources exist. - Follow-up surveys from 2000-2010s (examples: Public Citizen and academic papers) reported that among FDA pharmaceutical review division staff who worked for a certain period, the proportion who transferred to pharmaceutical companies or related consulting companies within 2-5 years after retirement reached approximately 20-30%. - In a 2016 JAMA Internal Medicine analysis, among FDA advisory committee members, the proportion receiving financial benefits (research funds, lecture fees, etc.) from companies averaged approximately 30-40%, and the voting behavior of members from industry showed a statistically observable tendency toward approval. - Among former FDA commissioners and vice commissioners, multiple cases of post-retirement positions as pharmaceutical company directors or senior advisors have been publicly reported, with major cases since 2010 confirmable through public resumes and corporate SEC filings. These movements occur under FDA ethics regulations (1-2 year cooling-off period based on 18 U.S.C. § 207), but employment after the period ends is not prohibited. ### EMA and European Records EMA subjects corporate employment of staff to pre-notification and review under transparency regulations (Regulation (EC) No 726/2004 and 2014 conflict of interest policy). - European Parliament and Court of Auditors reports regularly note cases of EMA former employees' employment in pharmaceutical companies, with at least dozens of movements recorded between 2015-2022. - Particularly common are cases of transfer from safety assessment divisions or rare disease pharmaceutical positions to industry, confirmed in EMA internal documents and European Ombudsman complaint records. - Academic papers (e.g., British Journal of Clinical Pharmacology) point out patterns where financial relationships develop between experts participating in EMA's scientific advice process and companies later receiving advice. ### Records in Japan (PMDA and Ministry of Health, Labour and Welfare) Since its establishment in 2004, PMDA has made partial disclosures regarding employee transfers to private companies. - Internal regulations of the Ministry of Health, Labour and Welfare and PMDA specify a 2-year post-retirement employment restriction, but in actual application, multiple cases confirm transfers to pharmaceutical companies or CROs (clinical research organizations) after staff leave review positions. - In Diet response materials and Ministry of Health, Labour and Welfare personnel records from the 2010s, several cases of PMDA reviewer-class retirees taking positions in company safety information management and development planning divisions are scattered. - While systematic academic surveys are fewer than in English-speaking countries, PMDA annual reports from 2018-2023 and independent administrative corporation evaluation committee materials demonstrate that pharmaceutical companies comprise a certain number among former employees' reemployment destinations. ### Structural Factors of Conflicts of Interest The above movements occur due to the following structural factors. 1. Asymmetry of Specialized Knowledge Regulatory authorities need personnel with practical experience in industry to maintain advanced review capabilities. Conversely, companies value personnel experienced in regulatory procedures, so mutual personnel exchange occurs. 2. Wage Level Differences Private sector compensation often exceeds civil service salaries, particularly in the US where pharmaceutical executive compensation reaches several multiples of senior FDA staff. This difference influences career choices after retirement. 3. Networks and Information Sharing When the same person works on both regulatory and company sides, pathways form for interpreting review standards and informal information transfer. Academic research suggests this pathway may statistically influence individual approval decisions. 4. Limitations of Post-Facto Regulation While cooling-off periods and disclosure obligations exist, enforcement is weak regarding post-period employment or indirect employment forms (consultant, subsidiary routes). Western cases show repeated use of these gaps. These factors arise structurally as personnel exchange between organizations, independent of individual intent. Public records and academic papers primarily analyze these structural aspects.